B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 — Trials · CancerIndex

Clinical trials

Registered studies

39 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 18
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 6%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02819804	Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	terminated	Phase 1	1	Northwestern UniversityOTHER	1	Feb 11, 2020	clinicaltrials
NCT02129062	Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia	terminated	Phase 2	3	National Cancer Institute (NCI)NIH	1	Jan 16, 2017	clinicaltrials